Takeda Pharmaceutical Forecast, price target & analysts
Takeda Pharmaceutical Target price 2025 - Analyst rating & recommendation
Takeda Pharmaceutical Classifications & Recommendation:
Takeda Pharmaceutical Price Target
| Target Price | JPY4,755.01 |
| Price | JPY4,182.00 |
| Potential |
13.70%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target Takeda Pharmaceutical 2026 .
The average Takeda Pharmaceutical target price is JPY4,755.01.
This is
13.70%
register free of charge
JPY5,570.00
33.19%
register free of charge
JPY4,200.00
0.43%
register free of charge
|
|
| A rating was issued by 17 analysts: 8 Analysts recommend Takeda Pharmaceutical to buy, 9 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Takeda Pharmaceutical stock has an average upside potential 2026 of
13.70%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Mar '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion JPY | 4,263.76 | 4,555.18 |
| 5.87% | 6.83% | |
| EBITDA Margin | 29.51% | 27.18% |
| 10.15% | 7.89% | |
| Net Margin | 3.42% | 3.09% |
| 57.42% | 9.75% |
15 Analysts have issued a sales forecast Takeda Pharmaceutical 2025 . The average Takeda Pharmaceutical sales estimate is
This results in the following potential growth metrics:
11 Analysts have issued an Takeda Pharmaceutical EBITDA forecast 2025. The average Takeda Pharmaceutical EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Takeda Pharmaceutical Analysts have issued a net profit forecast 2025. The average Takeda Pharmaceutical net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Mar '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share JPY | 92.09 | 88.78 |
| 54.92% | 3.59% | |
| P/E | 47.58 | |
| EV/Sales | 2.42 |
8 Analysts have issued a Takeda Pharmaceutical forecast for earnings per share. The average Takeda Pharmaceutical <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Takeda Pharmaceutical stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Takeda Pharmaceutical...
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
